Clinical Trial Update: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. [Phase 3]

View source ↗

Summary

Phase III randomized trial evaluating FCN-437c in combination with fulvestrant ± goserelin versus placebo with fulvestrant ± goserelin in HR+ HER2- advanced bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FCN-437c
• Fulvestrant (fulvestrant)
• Goserelin (Goserelin)

Snippet

Sponsor: Ahon Pharmaceutical Co., Ltd. | Conditions: Advanced Breast Cancer, Female Breast Cancer | Phase 3 | Status: UNKNOWN